New Edge Advisors, LLC Bio Line Rx Ltd. Transaction History
New Edge Advisors, LLC
- $15 Billion
- Q3 2024
A detailed history of New Edge Advisors, LLC transactions in Bio Line Rx Ltd. stock. As of the latest transaction made, New Edge Advisors, LLC holds 4,300 shares of BLRX stock, worth $14,319. This represents 0.0% of its overall portfolio holdings.
Number of Shares
4,300
Previous 4,300
-0.0%
Holding current value
$14,319
Previous $2,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding BLRX
# of Institutions
39Shares Held
3.22MCall Options Held
46.5KPut Options Held
6.3K-
Alyeska Investment Group, L.P. Chicago, IL866KShares$2.89 Million0.0% of portfolio
-
Cvi Holdings, LLC Wilmington, DE816KShares$2.72 Million4.05% of portfolio
-
Envestnet Asset Management Inc239KShares$796,4890.0% of portfolio
-
Morgan Stanley New York, NY198KShares$657,7980.0% of portfolio
-
Values First Advisors, Inc.166KShares$554,2750.02% of portfolio
About BioLineRx Ltd.
- Ticker BLRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 61,524,500
- Market Cap $205M
- Description
- BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials ...